Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors

Epigenetics

Volumn 3, Issue 3, 2008, Pages 157-163

  Tapia, Teresa ^a   Smalley, Susan V ^a   Kohen, Paulina ^b   Muñoz, Alex ^b   Solis, Luisa M ^a   Corvalan, Alejandro ^a   Faundez, Paola ^a   Devoto, Luigi ^b   Camus, Mauricio ^a   Alvarez, Manuel ^a   Carvallo, Pilar ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

BRCA1 promoter hypermethylation; BRCA1 protein expression; Breast cancer biopsies; Estrogen progesterone receptors; Hereditary breast cancer

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; HORMONE RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST BIOPSY; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GRADING; CLINICAL ARTICLE; CONTROLLED STUDY; FAMILIAL CANCER; FEMALE; GENE MUTATION; GENETIC SCREENING; GERM LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN HYPERMETHYLATION; PROTEIN METHYLATION;

EID: 49249136904     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.3.3.6387     Document Type: Article

References (32)

1. Miki Y, Swensen J, Shattuck-Eidens D, Futreal P, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266:66-71.
2. Gallardo M, Silva A, Rubio L, Alvarez C, Torrealba C, Salinas M, et al. Incidence of BRCA and BRCA2 mutations in 54 Chilean families with breast/ ovarian cancer, genotype-phenotype correlations. Breast Cancer Res Treat 2006; 95:81-7.
3. Smith S, Easton D, Evans D, Ponder B. Allele losses in the region 17q12-21 in familial breast and ovarian cancer involve the wild-type chromosome. Nature Genet 1992; 2:128-31.
4. Scully R, Livingston DM. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 2000; 408:429-32.
5. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998; 72:141-96.
6. Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999; 21:163-7.
7. Dobrovic A, Simpfendorfer D. Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res 1997; 57:3347-50.
8. Rice J, Massey-Brown K, Futscher B. Aberrant methylation of the BRCA1 CpG island promoter is associated with decreased BRCA1 mRNA in sporadic breast cancer cells. Oncogene 1998; 17:1807-12.
9. Mancini D, Rodenhiser D, Ainsworth P, O'Malley F, Singh S, Xing W, et al. CpG methylation within the 5' regulatory region of the BRCA1 gene is tumor specific and includes a putative CREB binding site. Oncogene 1998; 16:1161-9.
10. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 1995; 9:444-50.
11. Taylor J, Lymboura M, Pace PE, A'hern RP, Desai AJ, Shousha S, et al. An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non-familial breast cancers. Int J Cancer 1998; 79:334-42.
12. Wilson CA, Ramos L, Villaseñor MR, Anders KH, Press MF, Clarke K, et al. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet 1999; 21 236-40.
13. Wei M, Grushko TA, Dignam J, Hagos F, Nanda R, Sveen L, et al. BRCA1 promoter methylation in sporadic breast cancer is associated with reduced BRCA1 copy number and chromosome 17 aneusomy. Cancer Res 2005: 65:10692-9.
14. Honrado E, Osorio A, Milne R, Paz M, Melchor L, Cascón A, et al. Immunohistochemical classification of non-BRCA1/2 tumors identifies different groups that demonstrate the heterogeneity of BRCAX families. Mod Pathol 2007; 12:1298-306.
15. Frommer M, McDonald L, Millar D, Collis C, Watt F, Grigg G, et al. A genomic sequencing protocol that yields a positive display of 5-methylcitosine residues in individual DNA strands. Proc Natl Acad Sci 1992; 89:1827-31.
16. Herman J, Graft J, Myöhänen S, Nelkin B, Baylin S. Methylation-specific PCR A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci 1996; 93:9821-6.
17. Clarke S, Statham A, Stirzaker C, Molloy P, Frommer M. DNA methylation:bisulphite modification and analysis. Nat Protoc 2006; 1:2353-64.
18. Esteller M, Silva J, Dominguez G, Bonilla F, Matias-Guiu X, Lerma Enrique, et al. Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors. J Natl Cancer Inst 2000; 92:564-9.
19. Esteller M, Fraga M, Guo M, Garcia-Foncillas J, Hedenfalk I, Godwin A, et al. DNA methylation patterns in hereditary human cancers mimic sporadic tumorigenesis. Hum Mol Genet 2001; 10:3001-7.
20. Catteau A, Harris W, Xu C, Solomon E. Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer correlation with disease characteristics. Oncogene 1999; 11:1957-65.
21. Mirza S, Sharma G, Prasad C, Parshad R, Shrivastava A, Gupta S, et al. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. Life Sci 2007; 81:280-7.
22. Bianco T, Chenevix-Trench G, Walsh DC, Cooper JE, Dobrovic A. Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer. Carcinogenesis 2000; 21:147-51,
23. Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S, et al. BRCA1 promoter region hypermethylation in ovarian carcinoma a population-based study. Cancer Res 2000; 60:5329-33.
24. Matros E, Wang ZC, Lodeiro G, Miron A, Iglehart JD, Richardson AL. BRCA1 promoter methylation in sporadic breast tumors: relationship to gene expression profiles. Breast Cancer Res Treat 2005; 91:179-86.
25. Birgisdottir V, Stefansson OA, Bodvarsdottir SK, Hilmarsdottir H, Jonasson JG, Eyfjord JE. Epigenetic silencing and deletion of the BRCA1 gene in sporadic breast cancer. Breast Cancer Res 2006; 8:38.
26. Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, et al. Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade and histological type. Clin Cancer Res 2004; 10:2029-34.
27. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, et al. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005; 11:5175-80.
28. Fan S, Wang J, Yuan R, Ma Y, Meng Q, Erdos MR, et al. BRCA1 inhibition of estrogen receptor signaling in transfected cells. Science 1999; 284:1354-6.
29. Fan S, Yuan R, Ma YX, Meng Q, Goldberg ID, Rosen EM. Mutant BRCA1 genes antagonize phenotype of wild-type BRCA1. Oncogene 2001; 20:8215-35.
30. Hosey AM, Gorski JJ, Murray MM, Quinn JE, Chung WY, Stewart GE, et al. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. J Natl Cancer Inst 2007; 99:1683-94.
31. Read LD, Snider CE, Miller JS, Greene GL, Katzenellenbogen BS. Ligand-modulated regulation of progesterone receptor messenger ribonucleic acid and protein in human breast cancer cell lines. Mol Endocrinol 1988; 2:263-71.
32. Leung W, To K, Man E, Chan M, Bai A, Hui A, er al. Quantitative detection of promoter hypermethylation in multiple genes in the serum of patients with colorectal cancer. Am J Gastroenterol 2005; 100 2274-9.